Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer

CONCLUSIONS: Rarely does NAI result in pCR for patients with stage 2 or 3 ER+ BC. However, a significant proportion will have downstaged to allow for BCS. Local-regional recurrence after surgery is uncommon (1.5% at 5 years), supporting the use of BCS after NAI.PMID:36653664 | DOI:10.1245/s10434-022-12972-5

Source: Ann Oncol - January 18, 2023 Category: Cancer & Oncology Authors: Kelly K Hunt Vera J Suman Hannah F Wingate A Marilyn Leitch Gary Unzeitig Judy C Boughey Funda Meric-Bernstam Matthew J Ellis John Olson Source Type: research